-
Innovation Ranking
NewInnovation Ranking – OPKO Health Inc
OPKO Health Inc (OPKO) discovers, develops, manufactures, and commercializes novel diagnostic technologies and pharmaceuticals products. The company’s product portfolio includes 4K score test used for diagnosis of prostate cancer; Rayaldee (calcifediol), an extended-release capsule for treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease; and the Claros analyzer, a blood performance test. OPKO develops products using proprietary technologies including, Carboxyl Terminal Peptide (CTP) technology, Reversible PEGylation and AntagoNAT technology. It is advancing pipeline products targeted...
-
Product Insights
NewNet Present Value Model: OPKO Health Inc’s Pegapamodutide
Empower your strategies with our Net Present Value Model: OPKO Health Inc's Pegapamodutide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of OPKO Health Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of OPKO Health Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Transitional Cell Cancer (Urothelial Cell Cancer)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPK-88005 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPK-88005 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPK-88005 in Hemophilia B (Factor IX Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia B (Factor IX Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPK-88005 in Hemophilia B (Factor IX Deficiency) Drug Details:...
-
Product Insights
Hyperparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperparathyroidism - Drugs In Development, 2023’, provides an overview of the Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hyperphosphatemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Secondary Hyperparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Hyperparathyroidism - Drugs In Development, 2023’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hyperphosphatemia In Chronic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...